#ESC22: Cin­Cor CMO’s 17-year jour­ney in bring­ing a new hy­per­ten­sion drug to mar­ket con­tin­ues

BARCELONA — Six­teen years ago, Ma­son Free­man was “very dis­ap­point­ed.” A first-in-hu­man study of an al­dos­terone syn­thase in­hibitor, or ASI, had done what it was sup­posed to do: block al­dos­terone pro­duc­tion. But it al­so blocked cor­ti­sol.

So, his man­agers at No­var­tis scrapped the pro­gram that the decades-long Har­vard/Mass Gen­er­al physi­cian and a French pro­fes­sor had drummed up just a year ear­li­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER